Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: IDEAYA is a clinical-stage precision medicine oncology company focused on discovering and developing targeted therapeutics for patient populations selected using molecular diagnostics. The company has no products approved for commercial sale and has not generated product revenue since inception. Its strategy relies on a robust pipeline of synthetic lethality and direct targeting programs, supported by strategic collaborations with major pharmaceutical partners including GSK, Pfizer, Gilead, and Merck.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 |
|---|---|---|
| Collaboration Revenue | $7.0 | $23.4 |
| Research & Development Expenses | $294.7 | $129.5 |
| General & Administrative Expenses | $39.3 | $28.3 |
| Net Loss | $(274.5) | $(113.0) |
| Accumulated Deficit | $(622.8) | $(348.4) |
| Cash, Cash Equivalents & Marketable Securities | $1.1 billion | $632.6 million |
| Net Cash Used in Operating Activities | $(247.6) | $(115.2) |
Note: Revenue consists exclusively of collaboration revenue, primarily from the GSK Collaboration Agreement. There is no product revenue.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by 70% ($16.4 million) year-over-year. This was due to the completion of performance obligations related to the upfront payment and R&D services under the GSK Collaboration Agreement by the end of 2023. The $7.0 million recognized in 2024 was solely from a milestone payment for the IND clearance of IDE275 (GSK959).
- Expense Surge: Total operating expenses increased by 112% to $334.0 million. Research and Development (R&D) expenses rose 128% to $294.7 million. This increase was driven by:
- $75.0 million upfront payment for the IDE849 license from Hengrui Pharma.
- $6.5 million upfront and option exercise fees for the IDE034 license from Biocytogen.
- $64.1 million increase in fees to CROs/CMOs for advancing lead candidates.
- $15.6 million increase in personnel-related expenses.
- Liquidity Position: Cash and marketable securities increased significantly to $1.1 billion, bolstered by a July 2024 follow-on offering ($283.8 million net proceeds) and At-The-Market (ATM) offerings ($379.9 million net proceeds in 2024).
Guidance, Outlook, and Management Commentary
Outlook: Management expects to continue incurring significant losses for the foreseeable future as it advances clinical trials and prepares for potential commercialization. The company believes its current cash position is sufficient to fund planned operations for at least 12 months from the filing date (February 2025).
Key Pipeline Updates & Milestones:
- Darovasertib (PKC): Most advanced candidate. Completed dose optimization for the Phase 2/3 registration-enabling trial in metastatic uveal melanoma (MUM) in December 2024. Targeting a median PFS readout by year-end 2025. Initiating a Phase 3 neoadjuvant trial in the first half of 2025.
- IDE397 (MAT2A): Selected a move-forward Phase 2 expansion dose. Reported preliminary efficacy in MTAP-deletion urothelial cancer and NSCLC. Expanded collaboration with Gilead to evaluate combination with Trodelvy in NSCLC (February 2025).
- IDE849 (DLL3 ADC): Entered exclusive license with Hengrui Pharma (December 2024) for rights outside Greater China. Hengrui is eligible for up to $1.045 billion in payments. IDEAYA plans a U.S. IND submission in H1 2025.
- IDE275 (WRN) & IDE705 (Pol Theta): Both programs are in collaboration with GSK. IDE275 received IND clearance in October 2024, triggering a $7.0 million milestone. IDE705 is in Phase 1 dose escalation.
- New Candidates: Selected IDE892 (PRMT5), IDE034 (BsADC), and IDE251 (KAT6/7) as development candidates in late 2024, targeting IND filings in 2025.
Risks: The company faces significant risks related to clinical trial outcomes, regulatory approvals, and the need for additional capital. It relies heavily on third-party manufacturers and collaborators (e.g., GSK, Pfizer). Termination of the GSK collaboration would materially adversely affect financial condition.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.1 billion cash balance against the projected burn rate, given the 128% increase in R&D expenses and the lack of product revenue.
- Revenue Sustainability: Confirm the timeline for future milestone payments from GSK and other partners, as collaboration revenue dropped significantly in 2024 after the completion of initial performance obligations.
- Clinical Trial Progress: Monitor enrollment and data readouts for the darovasertib Phase 2/3 trial (targeting late 2025) and the neoadjuvant Phase 3 trial (initiating H1 2025), as these are critical for future valuation.
- Licensing Obligations: Review the financial impact of the new Hengrui ($75M upfront) and Biocytogen ($6.5M upfront) agreements and the associated future milestone payment obligations.
- Collaboration Dependencies: Assess the risk exposure related to the GSK Collaboration Agreement, which accounts for all current revenue and significant future potential milestones, and the potential impact of GSK terminating the agreement.